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ABSTRACT
Androgen receptors (ARs) play a critical role in the development of prostate 
cancer. Targeting ARs results in important salutary effects in this malignancy. Despite 
mounting evidence that ARs also participate in the pathogenesis and/or progression 
of diverse tumors, exploring the impact of hormonal manipulation of these receptors 
has not been widely pursued beyond prostate cancer. This review describes patterns 
of AR expression in a spectrum of cancers, and the potential to exploit this knowledge 
in the clinical therapeutic setting.
INTRODUCTION
Treatments targeting androgen receptors (ARs) have 
demonstrated efficacy in patients with prostate cancer. 
Despite a wealth of reports indicating that ARs may 
contribute to the growth and/or progression of numerous 
other malignancies, their precise role in cancers beyond 
those of the prostate is poorly understood. The aim of 
this review is to illuminate current data in the literature 
regarding the expression and functional impact of ARs 
in a range of solid tumors (Table 1), and to discuss the 
therapeutic implications of AR positivity.
Background
Androgen synthesis and androgen receptors: The 
goal of androgen deprivation or suppression therapy is 
to reduce the levels of male hormones (androgens) [1]. 
The major androgens capable of stimulating the androgen 
receptors include testosterone and dihydrotestosterone 
(DHT) [2]. In normal men, androgens are synthesized 
in the testes (interstitial Leydig cells) and adrenals. 
Testosterone is the principal circulating androgen in 
adult men, with >95% being of testicular origin [3] 
(under the regulatory control of the hypothalamic / 
pituitary axis), while the remainder originates from 
peripheral conversion of weaker precursors of adrenal 
origin: dehydroepiandrosterone (DHEA), DHEA sulfate, 
and androstenedione [4]. Adrenal androgens are under 
adrenocorticotropin hormone (ACTH) control [5]. The 
adrenals and peripheral conversion/synthesis of androgens 
do not make a major contribution to androgen effects in 
the normal man, but may become a significant residual 
source of AR stimulation in men undergoing androgen 
deprivation/suppression therapy. Skin, fat, liver, and 
urogenital systems are important peripheral sites of 
androgen production [6, 7]. 
Prostate cancer as a model for androgen deprivation 
therapy: Androgens stimulate AR+ cells to proliferate. 
Since the vast majority of prostate cancers are AR+, 
androgen deprivation (suppression) treatment was a 
rational approach for this malignancy, and has become 
a cornerstone of treatment for advanced prostate cancer 
(Table 2) [8]. Androgen deprivation can shrink or stabilize 
prostate tumors, but is not generally curative. There are 
protean ways to suppress androgen levels. These include:
• Surgical removal of the testes (castration or 
orchiectomy).
• Luteinizing hormone-releasing hormone (LHRH) 
analogs (reversible chemical castration). These drugs halt 
testosterone production by the testicles.
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Examples of these agents include leuprolide, 
goserelin, triptorelin, and histrelin [9]. When LHRH 
analogs are initiated, testosterone levels rise before falling, 
a phenomenon known as a “clinical flare” [10]. The flare 
can cause bone pain or spinal cord compression if tumors 
are present in these areas, as the tumors may have a short-
lived growth spurt. The flare can be prevented by giving 
anti-androgens for a few weeks when LHRN analogs are 
started. 
• Luteinizing hormone-releasing hormone (LHRH) 
antagonists. LHRH antagonists such as degarelix work 
like LHRH agonists, but they reduce testosterone levels 
more rapidly and do not induce a tumor flare like the 
LHRH agonists do [11]. 
• Anti-androgens. Anti-androgens impede the body’s 
ability to use androgens, usually by blocking the androgen 
receptor. Even after orchiectomy or during treatment 
with LHRH analogs, the adrenal glands still synthesize 
small amounts of androgens. Drugs of this type include 
flutamide, bicalutamide, and nilutamide [12].
• Other androgen-suppressing drugs. Estrogens were 
once the main alternative to orchiectomy for men with 
advanced prostate cancer. Because of their toxic effects 
[13] (including blood clots and breast enlargement), oral 
estrogens have been largely replaced by LHRH analogs 
and anti-androgens [14]. It has been suggested that 
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parenteral estrogen may avoid long term toxicity [15]. 
Ketoconazole, first used for treating fungal infections, 
blocks production of androgens. It offers a quick way to 
lower testosterone levels, and it is used in countries where 
abiraterone has yet to be approved [16]. Abiraterone 
inhibits 17 α-hydroxylase/C17,20 lyase (CYP17A1), 
an enzyme that is expressed in testicular, adrenal, and 
prostatic tumor tissues. CYP17 catalyzes key reactions 
in the testosterone synthesis pathway; inhibition of 
CYP17 [17] activity by abiraterone thus interferes with 
the processes in the testes and the adrenals leading to 
testosterone production. 
Androgen deprivation has important side effects 
[18, 19], especially in men: reduced or absent libido, 
impotence; hot flashes, gynecomastia, osteoporosis and 
fractures, attenuated mental acuity, loss of muscle mass, 
depression, and fatigue
THE ROLE OF ANDROGENS IN DIVERSE 
TUMORS
Although the historic emphasis has been on 
prosecuting androgen receptors in prostate cancer, it 
turns out that androgens have a vital role in numerous 
other cancers as well (Supplemental references 1-119). 
It is conceivable that interrogation of androgen receptor 
positivity and treatment with androgen antagonistic agents 
could therefore be an effective strategy in these cancers. 
I. HEAD AND NECK CANCERS
Salivary gland tumors: Remarkable similarities 
between breast cancer and salivary gland tumors have 
been documented [S1-S3]. Not only is HER2/neu 
expression frequent in these tumors, but estrogen receptors 
(ER) and progesterone receptors (PR) are expressed in 
33.3% (13/69) and 86.9% (60/69), respectively, in the 
pleomorphic adenoma subtype [S3]. AR positivity has 
also been documented in salivary duct carcinomas [S1, 
S4-S6]. Nasser et al. [S2] reported a series of 78 formalin-
fixed, paraffin-embedded salivary gland tumors with 
strong positivity for AR in 100% (14/14) of carcinoma 
ex-pleomorphic adenomas and 100% (6/6) of salivary 
duct carcinomas. Fan et al. [S5] reported AR positivity 
rates as high as 92% (11/12) in salivary duct carcinomas. 
AR reactivity was also seen in 20% (2/10) of acinic cell 
carcinomas, 20% (2/10) of mucoepidermoid carcinomas, 
and 20% (2/10) of adenoid cystic carcinomas [S2]. In 
the same study all 26 benign salivary gland tumors were 
negative for expression of AR [S2]. 
In regard to treatment, Locati et al. [S7] reported a 
complete remission with androgen deprivation therapy in 
a patient with recurrent AR-expressing adenocarcinoma 
of the parotid gland. Kuroda et al. [S8] reported a partial 
response after one course of anti-androgen therapy and 
palliative chemotherapy with paclitaxel in a patient with 
advanced salivary duct carcinoma.
Thyroid carcinoma: Thyroid cancer is the most 
frequently occurring endocrine-related malignancy 
[S9, S10]. The most common form of thyroid cancer 
Table 2: Examples of Anti-Androgens Approved by the Food and Drug Administration (FDA) agents to treat prostate 
cancer* 
Drug name Mechanism of action Indication Examples
Leuprolide acetate GnRH** agonists Palliative treatment of advanced prostatic cancer.
Goserelin acetate GnRH agonists Palliative treatment of advanced prostatic cancer.
Triptorelin pamoate GnRH agonists Palliative treatment of advanced prostatic cancer.
Histrelin acetate GnRH agonists Palliative treatment of advanced prostatic cancer.
Degarelix acetate GnRH antagonists Palliative treatment of advanced prostatic cancer.
Bicalutamide Binds to androgen receptor Metastatic prostate cancer
Flutamide
Competes for AR
 the 
 and dihydrotestosterone for the 
androgen receptor
“””
Nilutamide Blocks AR Advanced prostate cancer
Abiraterone acetate CYP17A1 inhibitor Metastatic castration-resistant prostate cancer who have received prior docetaxel.
Enzalutamide Androgen receptor inhibitor Metastatic castration-resistant prostate cancer who have received prior docetaxel.
Radium Ra 223 
dichloride
Alpha-particle emitting Symptomatic bone metastases and no known visceral 
metastatic disease.
* Data from www.fda.gov (Accessed August 11, 2014).
** AR = androgen receptor; GnRH: gonadotropin releasing hormone
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is papillary (~79%), followed by follicular (~14%), 
medullary (~2%), anaplastic (~1%) and other histological 
subtypes (~4%) [S11]. There are significant rates of 
recurrence with current therapeutic approaches such as 
surgery or radioactive iodine therapy [S9]. Because both 
benign and malignant thyroid lesions are more common 
in women than in men, it has been suggested that sex 
hormones play a role. Certainly somatic mutations in 
BRAF, RAS and RET, all described in thyroid cancer, are 
not known to account for the gender disparity [S10]. 
Bléchet et al. [S12] showed AR positivity 
by immunohistochemistry (IHC) in 14% (4/28) of 
medullary thyroid carcinomas. Testosterone increased 
dose-dependent proliferation of AR+ human papillary 
thyroid cancer cell lines; whereas flutamide, inhibited 
testosterone-induced cell proliferation [S13]. Wiseman 
et al. [S14] examined differentiated thyroid cancer and 
found AR+ in 50.5% (50/99) compared to 2% (2/100) of 
benign lesions. Prinz et al. [S15] showed AR+ in 17 of 31 
cases of thyroid cancer, including 80% (4/5) of papillary 
carcinomas and 80% (4/5) of follicular adenomas. Despite 
high AR expression in thyroid cancer, there are only 
anecdotal reports of therapeutic hormonal manipulation 
[S16].
Thymoma and thymic carcinoma: Ishibashi et al. 
[S17] examined patients with thymoma and found AR+ 
nuclear immunoreactivity by IHC in 15% of patients 
(20/132). Mimae et al. [S18] studied thymic epithelial 
tumors (103 thymomas and 37 thymic carcinomas) 
and found that 23.6% expressed AR. The World Health 
Organization (WHO) classified epithelial thymic tumors 
into six types including A, AB, B1, B2, B3, and thymic 
carcinoma. Because the histological differential diagnosis 
between type B3 thymoma and thymic carcinoma can 
be challenging, Khoury et al. [S19] proposed that AR 
might be useful for pinpointing the diagnosis, particularly 
because cytoplasmic AR was found in 58.8% (10/17) of 
type B3 thymomas versus 0% (0/12) of thymic carcinomas 
[S19]. Preclinical data suggest that blocking AR with 
5-alpha-dihydrotestosterone can initiate apoptosis in 
thymoma cells [S20].
Juvenile nasopharyngeal angiofibroma: Several 
publications have documented that these benign 
hormone-dependent tumors, particularly the ones prone to 
affecting adolescent males, express AR [S21, S22]. IHC 
results showed AR+ in 75% (18/24) of nasopharyngeal 
angiofibroma cases [S23]. Montag et al. [S24] showed that 
AR is expressed in 38.4% (5/13) of patients. These results 
translated to the clinic where 4 of 5 patients with juvenile 
nasopharyngeal angiofibroma demonstrated an average 
shrinkage of 44% following flutamide [S25]. 
Head and neck carcinomas :¨ Bianchini et al. [S26] 
studied tissue from 15 patients with laryngeal carcinoma 
but found no expression of AR (0%) [S26]. Virolainen 
et al. [S27] found 10% (1/10) AR positivity in cell lines 
derived from laryngeal squamous cell carcinoma and 
0% (0/9) AR positivity in non-laryngeal head and neck 
squamous tumors. Mattox et al. [S28] evaluated flutamide 
in patients with laryngeal carcinoma and, surprisingly, 
short-lived partial responses were seen in 3 of 9 patients. 
AR levels did not correlate with response [S28].
II. CUTANEOUS MALIGNANCIES
Melanoma: AR reactivity was present in 40% 
of melanomas; however, it was also observed in 41% 
of normal skin [S29]. In contrast, a different report 
(N=142 patients with malignant melanoma) discerned 
AR positivity in only 4% of cases [S30]. Morvillo et al. 
[S31] showed ARs in human melanoma cell lines, with 
tumor growth after exposure to dihydrotestosterone versus 
significant inhibition of proliferation after tamoxifen or 
flutamide [S32]. Ketoconazole, an androgen synthesis 
inhibitor, was shown to abrogate the metastatic potential 
of melanoma cell lines in mice [S33]. 
Basal cell carcinoma: Katona et al. [S34] and 
Izikson et al. [S35] reported AR expression in 65% 
(20/31) and 78% (25/32), respectively, of basal cell 
carcinoma cases; they suggested that the expression was 
high enough to help distinguish basal cell carcinoma from 
other skin conditions with low or negative AR expression, 
such as benign trichoblastic tumors and desmoplastic 
trichoepithelioma.
III. SARCOMA
Limited studies of AR in sarcomas have been 
performed.
Osteosarcoma: AR+ has been demonstrated 
in 28.5% (8/28) to 50.8% (33/65) of osteosarcomas 
[S36,S37]. Proliferation of osteosarcoma cell lines in 
vitro was stimulated by estradiol, progesterone, and 
5 alpha-dihydrotestosterone; whereas growth was 
abrogated by AR antagonists as fulvestrant, mifepristone, 
and hydroxiflutamide. Interestingly, higher levels of 
AR correlated with a higher degree of differentiation. 
In preclinical models, the adrenal androgen synthesis 
inhibitor ketoconazole prompted apoptosis in human 
osteosarcoma cells [S38]. 
Other malignant sarcomas: We were unable to find 
AR expression data regarding gastrointestinal stromal 
tumors in the literature [S39, S40]. In 1980, Walker et 
al. [S41] reported steroid receptors in malignant skeletal 
malignancies, including four cases of osteosarcoma, two 
chondrosarcomas, one malignant giant cell tumor, and one 
Ewing’s sarcoma. Cytoplasmic AR and PR were expressed 
in three of seven cases (43%) [S41]. Ziegler et al. [S42] 
found 0% (0/22) AR expression in tissue from 22 patients 
with Kaposi’s sarcoma. 
IV. GENITOURINARY MALIGNANCIES
Testicular germ cell tumors: There was no AR 
staining in embryonal carcinoma, mature teratoma, 
seminoma, or mixed germ cell tumors, although trace AR 
expression was found in 3 out of 5 cases of endodermal 
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sinus tumors [S43]. In a small study of seminomas, AR 
expression was detected in 45% of cases (N = 18) [S44].
Renal cell carcinoma: AR expression has been 
demonstrated in 14.2% (3/21), 14.8% (27/182) and 42% 
(5/12) of renal cell carcinomas [S45-S47]. AR positivity 
was associated with a significantly better progression-
free survival (PFS) compared to AR negativity in renal 
cancer [S45]. Brown et al. [S46] demonstrated AR 
immunoreactivity in 5 of 12 of patients with primary and 
in 1 of 5 of patients with metastatic clear cell renal cell 
carcinoma. Based on a small number of patients, Nakano 
et al. [S15] hypothesized that hormonal manipulation 
exerted no antineoplastic effect vis-a-vis tumor shrinkage, 
but did prolong survival in the subgroup with hormonal 
receptor positivity. A phase II trial of flutamide, a 
nonsteroidal antiandrogen, in 25 patients with advanced 
renal cell cancer, demonstrated one partial response for 
more than nine months and two patients maintained stable 
disease for six and 15 months, respectively [S15]. AR 
expression was seen in 25% (3/12) of biopsied patients.
Adrenocortical carcinomas: Because chemotherapy 
is effective in only a minority of patients with 
adrenocortical carcinomas, steroidogenesis inhibitors such 
as ketoconazole, mitotane, etomidate and metyrapone, 
have been used as single agents or combined with 
cytotoxic chemotherapy [S48]. Barzon et al. [S49] 
found that 38% (6/16) of patients with adrenocortical 
carcinoma were AR+ by IHC analysis. Rossi et al. 
[S50]] demonstrated AR RNA in human adrenocortical 
cancer cell lines. Ketoconazole reduces adrenal steroid 
biosynthesis by inhibiting cytochrome P450-dependent 
adrenal enzymes and is effective in reducing hormonal 
levels in virilizing adrenocortical carcinomas. However, 
generally no tumor shrinkage has been seen [S51, S52].
Bladder cancer: AR positivity has been found 
in 13% to 51% of bladder tumors [S53-S55] but not in 
normal bladder tissue [S55]. Loss of AR correlated 
with higher grade tumors [S55]; on the other hand, AR 
positivity was more frequent (71%) in metastatic disease 
than in primary tumors [S54]. There was no significant 
difference in the rate of AR positivity between men and 
women, despite the fact that bladder cancer is more 
common in men [S53]. Androgen blockage by flutamide 
in vitro as well as in vivo in mouse xenograft models 
with human AR-expressing bladder cancer cell lines 
attenuated proliferation and tumor growth [S56]. Hameed 
et al. [S57] assessed the combination of ketoconazole 
and all-trans retinoic acid in 16 patients with superficial 
bladder cancer, and demonstrated tolerable toxicity and 
reduced recurrence rate, albeit in the context of a small 
uncontrolled study. 
Prostate cancer: The discussion of prostate cancer 
herein is limited as AR and prostate cancer has been 
reviewed extensively elsewhere. Briefly, prostate cancer 
is a prime example of the potential for therapeutically 
manipulating hormonal levels (Table 2). This is feasible 
because strong nuclear AR reactivity is the norm in 
more than 95% of the samples studied [S58]. There is 
a high correlation between AR expression and response 
to hormonal treatment, and anti-androgens are therefore 
the mainstay of therapy for patients with prostate cancer 
[S59, S60]. Frequent AR positivity is found in more highly 
differentiated versus poorly differentiated tumors; further, 
AR was rarely seen in prostate tumors of patients who had 
received long-standing hormonal therapy [S61]. 
V. LUNG MALIGNANCIES
Non-small cell lung cancer: Kaiser et al. [S62] found 
AR expression in 70.5% (12/17) of non-small cell lung 
cancer cases. Rades et al. [S63] retrospectively found 31% 
(20/64) AR positivity in patients who received radiation 
for stage II/III non-small cell lung cancer. 
Small cell lung cancer: Kaiser et al. [S62] mentioned 
that hormonal receptor expression was almost non-existent 
in the small cell lung cancer cell lines. Maasberg et al. 
[S64], however, demonstrated growth stimulation by 
testosterone and growth inhibition by flutamide in selected 
AR+ small cell lung cancer cell lines. 
VI. GASTROINTESTINAL MALIGNANCIES
Gastric carcinomas: AR positivity has been found 
in 12.5% (2/16) to 39% (46/117) of gastric cancers 
[S65-S67]. AR positivity may correlate with poorer 
survival [S66]. 
Esophageal carcinomas: Yamashita et al. [S68] 
found AR positivity in two cases of human esophageal 
cancer xenografts implanted into nude mice; tumor 
progression was fueled by testosterone and inhibited by 
castration. Tihan et al. [S69] documented AR reactivity 
in 45% (5/11) of adenocarcinomas and 21.4% (3/14) of 
squamous cell carcinomas of the esophagus, respectively. 
Esophageal cancer seems to be more frequent in men than 
in women. However, no difference in the rate of positivity 
between genders was seen, though the numbers of patients 
were small, precluding definite conclusions. Interestingly, 
survival was similar regardless of AR status [S69]. Of 
possible interest, the Survival Epidemiology and End 
Results (SEER) registries database showed that patients 
with prostate cancer are less likely to develop esophageal 
adenocarcinoma [S70]. The relationship between these 
facts and treatment with androgen deprivation remains 
unexplored.
Pancreatic adenocarcinomas: Tumor progression 
in a nude mice xenograft model was stimulated 
by testosterone and inhibited by the anti-androgen 
cyproterone acetate [S71]. However, Targarona et al. 
[S72] found no AR expression in 12 biopsies of exocrine 
pancreatic neoplasia. A phase II study of the anti-androgen 
flutamide in an unselected population of 14 patients with 
advanced pancreatic adenocarcinoma yielded no objective 
responses [S73]. Subsequently, a randomized trial showed 
encouraging prolongation of median survival to 8 months 
in the flutamide group compared to 4 months in the 
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placebo group [S74]. A counterpoint, however, is the fact 
that patients with advanced pancreatic carcinoma have 
lower than expected testosterone secondary to malnutrition 
and consumption [S75]. In a preclinical model Konduri et 
al. [S76] did not show any significant improvement from 
combining flutamide with gemcitabine or bevacizumab. 
Since estrogen receptors may also be expressed in 
pancreatic cancer; the relationship between androgen and 
estrogen, when designing clinical trials testing hormonal 
blockade, will be particularly important in malignancies 
that express both receptors [S77, S78].
Colorectal adenocarcinomas: Tutton et al. [S79] 
confirmed that colon tumor cell proliferation was 
enhanced by testosterone and cell growth was attenuated 
by flutamide. Stebbing et al. [S80] found cytosolic 
AR in 39% (9/23) of rectal and 38% (5/13) of cecal 
adenocarcinomas. Several authors have described AR 
positivity in almost all samples of both colon tumors 
and normal mucose [S81, S82], while others have shown 
smaller, but still significant, percentage of AR positivity 
(32% colon tumors; 67% non-tumor tissue) [S83]. Further, 
ketoconazole has antiproliferative effects in human colon 
cancer cell lines [S84]. In preclinical rat models, cell 
proliferation in colon tumors was triggered by testosterone 
and inhibited by flutamide [S79]. However, the fact that 
normal colorectal mucosa expresses AR might blunt the 
usefulness of AR inhibitors in colorectal cancer.
VII. CONNECTIVE TISSUE TUMORS
Desmoid tumors: Ishizuka et al. [S85] documented 
AR expression in 52.9% (14/27) of patients with desmoid 
tumors. Goserelin, a gonadotropin releasing hormone 
agonist, resulted in stable disease in two patients with 
desmoid tumors for 4 and 16 months, respectively [S86]. 
Bauernhofer et al. [S87] reported a case of inoperable 
intra-abdominal desmoid tumor that decreased in size after 
treatment with goserelin acetate and low-dose tamoxifen 
for 17 months. 
VIII. CENTRAL NERVOUS SYSTEM 
MALIGNANCIES
Glioblastoma multiforme and other intracranial 
tumors: In preclinical studies, testosterone stimulated 
proliferation of glioblastoma multiforme cell lines [S88]. 
Chung et al. [S89] documented AR positivity in 40% 
(4/10) of glioblastoma multiforme cases, 28% (5/18) 
of grade I/II astrocytomas and 75% (3/4) of anaplastic 
astrocytoma. Lee et al. [S90] found AR+ in 42% (8/19) of 
patients with meningioma. 
VIII. GYNECOLOGIC MALIGNANCIES
Cervical cancer: One study demonstrated the 
expression of AR by immunohistochemistry in 100% 
(30/30) of normal epithelium, 100% (30/30) of low-grade 
cervical intraepithelial neoplasia, and 63% (19/23) of 
high-grade cervical intraepithelial neoplasia, as well as 
in 23% (3/13) of invasive squamous cell carcinoma. The 
authors suggested the loss of AR expression is a common 
occurrence in malignant cervical transformation [S91]. 
Even so, the fact that significant subsets of gynecologic 
cancers express AR may have clinical relevance.
Uterine cancer: Yang et al. [S92] found that AR 
positivity was the most robust variable associated with 
the risk of endometrial cancer. Ito et al. [S93] found AR 
reactivity in 88.6% (39/44) of endometrial carcinomas. 
Brys et al. [S94] found AR expression in 8% (1/12) 
of normal endometrium compared to 16% (4/25) of 
endometrial cancers. The reasons for this variability may 
relate to lack of standardized methodology.
Uterine sarcoma: A review of 65 cases of uterine 
sarcoma revealed 0% (0/65) AR+ [S95]. In contrast, 
Moinfar et al. [S96] found AR reactivity in 45% (9/20) 
of malignant endometrial stromal neoplasms. As benign 
leiomyomas are responsive to hormonal manipulation; 
Leitao et al. [S97] showed AR expression in 32% (6/19) of 
benign uterine leiomyoma and in 40% (10/25) of uterine 
leiomyosarcoma. AR positivity was predictive of a lower 
risk of recurrence although, after controlling for stage, 
AR was not significantly associated with overall survival 
improvement [S97]. 
Ovarian cancer: Testosterone binding sites have been 
found in 43% of normal ovaries, 40% of benign ovarian 
tumors, and 60.5% of ovarian adenocarcinomas [S98]. 
Elattar et al. [S99] noted that AR-expressing epithelial 
cells in ascitic fluid from patients with ovarian cancer 
were stimulated by dihydrotestosterone and inhibited by 
bicalutamide. AR expression was significantly reduced in 
paired samples after chemotherapy which might explain 
the lack of response to hormonal blockade in heavily 
pre-treated patients [S99]. Jones et al. [S100] studied 
steroid cell ovarian tumors, finding AR immunoreactivity 
in 64% (9/14) of samples. High AR expression in 18% 
(28/154) of epithelial ovarian cancer was reported [S101]. 
Patients with AR-positive serous tumors had improved 
disease-specific survival [S101]. Additionally, reports of 
transsexuals who developed ovarian cancer in the setting 
of androgen supplementation suggest a carcinogenic role 
for AR [S102]. In regard to treatment, a phase II trial of 
goserelin and bicalutamide in 35 patients with epithelial 
ovarian cancer did not prolong PFS [S103, S104]. Because 
chemotherapy reduces AR expression, anti-androgen 
therapy may be more effective early in the disease [S104]. 
One study demonstrated dissimilar AR reactivity within a 
single ovarian neoplasm, attesting to tumor heterogeneity 
[S105]. In a phase II trial, 32 patients with advanced 
ovarian neoplasia received a minimum of two months of 
flutamide resulting in one complete response for 73 weeks, 
one partial response for 44 weeks, and partial responses in 
28% (9/32) for a median of 24 weeks [S106]. A case report 
documented a patient with Leydig cell ovarian tumor, an 
androgen-producing neoplasm, which responded to the 
GnRH-analogue triptoreline [S107]. Because androgen 
receptors are frequently expressed in epithelial ovarian 
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cancer, investigation of newer anti-androgens in this 
disease may be worthwhile [S108].
VIII. BREAST CANCER
Peters et al. studied invasive breast ductal 
adenocarcinomas, finding 56% AR positivity by IHC, and 
expression was inversely associated with 10-year survival 
[S109]. In HER2/-positive breast malignancies, AR 
expression was found in 85.6% (89/104). AR-negative/
estrogen receptor-negative was the most aggressive 
phenotype and correlated with high-grade tumors [S110]. 
Similarly, Hu et al. [S111] documented AR positivity 
in 78.7% of 1,467 patients with breast cancer. Pristauz 
et al. [S112] studied the relationship between AR and 
BRCA mutations in a population of patients constituted 
by 32% (43/135) BRCA1 and 13% (18/135) BRCA2. 
Interestingly, AR reactivity was seen in 30% (13/43) of 
BRCA1 and in 78% (14/18) in BRCA2, suggesting that 
many ER-/PR- BRCA-mutant tumors are actually AR 
positive [S112]. A higher number of breast carcinomas 
were found to express AR (77%) compared to ER (61%) 
and PR (60%) in 980 cases, with more than 50% of triple 
negative tumors expressing AR [S113]. The fact that 
AR+ was lost by the time of autopsy (5/11) implies loss 
of AR expression in end-stage metastases [S114]. From a 
molecular standpoint, Collins et al. [S115] studied 2,171 
invasive breast malignancies with tissue microarrays, 
dividing them into luminal-A (64%), luminal-B (15%), 
basal-like (11%), and HER2 (6%). AR expression was 
seen in 77% of invasive breast malignancies divided into 
Figure 1: The road to (androgen) independence. AR-negative prostate adult stem cells generate AR-negative transit amplifying 
cells, AR-negative intermediate cells and AR-positive luminal secretory cells. Once therapeutic circulating androgen blockade ensues, 
AR-positive luminal cells die, giving origin to the adaptive (selected AR-positive luminal cells will continue to thrive despite lack of 
androgen exposure) and clonal theory of resistance (pre-existent AR-negative cells develop into a malignant clone). Castration-resistant 
prostate cancer might develop via ligand-dependent (tissue steroidogenesis, AR mutations, AR amplification) and ligand-independent 
pathways (heightened AR nuclear translocation, AR cross-talk with additional pathways, disturbing the balance between co-activators and 
co-repressors). 
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luminal-A (91%), luminal-B (68%), basal-like (32%), 
and HER2 (59%). Interestingly, AR expression was seen 
in 86% of 246 cases of ductal carcinoma in situ [S115]. 
Breast cancer cell lines may be at least AR-dependent 
[S116, S117]. Other preclinical studies in human breast 
cancer cell lines showed that AR overexpression induced 
tamoxifen resistance which was reversed by the AR 
antagonist bicalutamide [S118]. In regard to treatment, 
Gucalp et al. [S119] report on a multicenter phase II trial 
bicalutamide for patients with AR+/ER-/PR- breast cancer 
showed a clinical benefit rate of 19%.
DISCUSSION
Therapeutic implications of AR across 
malignancies: Lessons from prostate cancer: During 
the last several decades, androgen deprivation (Table 2, 
Figure 1) has been standard of care for metastatic prostate 
cancer; however, most patients eventually develop 
disease progression despite pharmacologic suppression 
of testosterone levels [20-22], denoted as castration-
resistant prostate cancer (Figure 2) perhaps mediated by 
androgen independence (Figure 1) [23, 24]. The goals 
of hormonal deprivation therapy for prostatic cancer are 
to decrease circulating plasma testosterone to castration 
levels and to block residual androgen at the cellular 
level (Figure 3). While orchiectomy is very effective at 
achieving some of these goals, it does not halt conversion 
of residual adrenal androgens to dihydrotestosterone 
(DHT). Certainly, the common examples of potent 
androgens include testosterone and DHT, which can 
directly stimulate androgen receptors. Subsequent 
therapies were added to the hormonal armamentarium 
including, but not limited to, bicalutamide, a competitive 
Figure 2: The fate of testosterone in prostatic tissues. Testosterone circulates in the blood and is bound to albumin, whereas 
free testosterone is introduced into prostate cells and is subsequently converted to DHT by 5-alpha-reductase. Binding of DHT to the 
AR induces dissociation from HSPs and receptor phosphorylation. The AR dimerizes and can bind to androgen-response elements in the 
promoter regions of target genes, leading to growth, survival and production of PSA. Enzalutamide, formerly called MDV3100, exerts 
its mechanism of action during several steps in the AR signaling pathway including inhibition of AR binding to androgens, inhibition of 
nuclear translocation of AR, inhibition of AR association to DNA, and AR amplification. As some of those aberrations may occur late in 
the disease, it is unknown at this point if enzalutamide will have a role upfront in the management of prostate cancer. Abbreviations: AR, 
androgen receptor; DHT, dihydrotestosterone; GTA, general transcription activation; HSP, heat-shock protein; SHBG, sex-hormone-binding 
globulin; AKT, akt serine/threonine kinase; DHEA, dihydroepiandrosterone; ERK, extracellular signal-regulated kinase; P, phosphorylated 
residues; PI3K, phosphoinositide 3-kinase; PTEN, phoshatase and tensin homolog. 
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non-steroidal androgen receptor antagonist; flutamide, a 
non-steroidal anti-androgen; and luteinizing hormone-
releasing hormone (LHRH) or gonadotropin-releasing 
hormone (Gn-RH) [25]. Leydig cells, which are located 
in the testes, are dependent on LH to produce and secrete 
testosterone. Gn-RH is a hypothalamic decapeptide that 
governs the synthesis of pituitary LH; thus synthetic Gn-
RH analogues were initially developed to treat infertility 
in cases of endogenous Gn-RH deficiency. Long-term 
administration of supra-physiologic Gn-RH produce the 
paradoxical effect of pituitary overstimulation including 
pituitary desensitization to Gn-RH, breakdown of 
physiological feedback systems, down-regulation of Gn-
RH receptors, depletion of releasable LH content, and 
reduction of testosterone secretion to castrate levels. It is 
not, therefore, surprising that high-dose Gn-RH analogues 
became a major therapeutic option in prostate cancer, as 
they bypass the need for orchiectomy [26]. Exogenous 
estrogens indirectly affect the prostate by disturbing the 
hypothalamus-pituitary-testes axis as estrogens inhibit the 
release of Gn-RH from the hypothalamus [27]. Recently, 
the realization that non-gonadal sources of androgens, 
such as the adrenal glands and intra-tumoral production, 
might be critical in the progression of prostate cancer led 
to the development of abiraterone acetate, an oral specific 
inhibitor of CYP17A1, which is a rate-limiting enzyme 
in androgen (and estrogen) synthesis that, when targeted, 
specifically suppresses adrenal androgens [28]. A novel 
alternative is the use of intermittent androgen suppression 
which holds the promise of decreasing toxicity while 
maintaining efficacy, although the role of intermittent 
therapy in the metastatic setting remains a challenge 
[29]. Hussain et al. [30] has studied intermittent versus 
continuous androgen deprivation in hormone sensitive 
metastatic prostate cancer patients in a phase III trial and 
their published final results are eagerly awaited. In the 
non-metastatic setting, Crook et al. [31] confirmed that 
intermittent androgen deprivation showed non-inferior 
overall survival when compared to continuous therapy 
after prostate irradiation.
Figure 3: Androgen blockade plus mTOR inhibitors: A prime candidate for combination hormonal treatment. The 
mTORC2/AKT/AR pathway (red arrows) leads to tumor cell proliferation. Rapamycin combined with bicalutamide has an apoptosis-
inducing effect in prostate cancer. Rapamycin inhibits both mTOR complexes, mTORC1 with raptor and mTORC2 with rictor; 
nevertheless abrogation of mTORC2, a kinase for AKT phosphorylation, further inhibits the AR transcription cascade in an AKT-dependent 
manner. As a counterpoint, abrogation of mTORC1 produces AKT/AR-independent apoptosis, though it continues to stimulate the AR 
transcriptional cascade and AKT phosphorylation. According to the suggested cross-talk, it would take a combination of androgen blockade 
plus mTOR inhibitors to fully abrogate the mTORC2/AKT/AR pathway. Barnett et al. [44] found that, out of 47 tumors evaluable by 
immunohistochemistry, 36% had PTEN loss which was associated with an increased relapse in high risk prostate cancer treated with 
chemotherapy followed by surgery. PTEN loss activates the AKT/mTOR pathway [45] thus supporting the use of mTOR inhibitors in this 
condition. Abbreviations: AR, androgen receptor; AKT, aKT serine/threonine kinase. 
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Finally, there are novel therapeutic agents including 
the once-daily androgen receptor signaling inhibitor 
enzalutamide, previously called MDV3100 [32, 33] 
(Figure 3), which significantly prolonged overall survival 
in a randomized phase III trial that involved 1,199 men 
with castration-resistant prostate cancer [34]. Such results 
triggered the Food and Drug Administration to approve 
enzalutamide in August of 2012 for the treatment of 
patients with metastatic castration-resistant prostate 
cancer who have previously received docetaxel. The 
recent wave of novel anti-androgen agents, as abiraterone 
and enzalutamide, serves as proof-of-principle that AR 
signaling continues even in the so-called castration-
resistant prostate cancer population [35].
Tolerance of Anti-Androgens: Hormonal therapy 
is not devoid of side effects, and depending on the agent 
used, toxicity can include increased risk of fractures, 
increased lipoproteins, decreased insulin sensitivity, 
increased cardiovascular disease, low libido and 
emasculation [36]; and such toxicity must be kept in mind 
during the design of future clinical trials.
Overcoming resistance to AR targeted therapy: 
Relevant molecular pathways: The mTOR (mammalian 
target of rapamycin) pathway has been hailed as a possible 
target for suppressing prostate malignancies (Figure 
3), as the PI3K/AKT components of the pathway are 
upregulated in hormone-refractory prostate neoplasia, and 
because the combination of rapamycin and bicalutamide 
produces apoptosis in prostate cell lines [37-39]. Indeed, 
this pathway is deregulated in up to 65% of prostate 
cancers, most commonly due to PTEN loss, and less 
commonly related to PIK3CA amplification or mutation 
[40]. Wang et al. described the regulation of androgen 
receptor transcriptional activity by rapamycin in prostate 
cancer cell proliferation and survival [38]. Furthermore, 
there seems to be cross-talk between AR and the epidermal 
growth factor receptor (EGFR) (Figure 3), which in turn 
activates the expression of mTOR [41]. Gonzalez-Angulo 
et al. [42] found significantly higher AR levels in breast 
cancer patients with kinase domain PIK3CA mutations 
versus wild-type PIK3CA. Wang et al. [43] hypothesized 
that AR halts PTEN transcription in the prostate in contrast 
to the breast, in which AR promotes PTEN transcription. 
Barnett et al. [44] found that, out of 47 tumors evaluable 
by IHC, 36% had PTEN loss which was associated with an 
increased relapse in high risk prostate cancer treated with 
chemotherapy followed by surgery. PTEN loss activates 
the PI3K/AKT/mTOR pathway [45] thus supporting the 
use of mTOR inhibitors in this condition. 
While both EGFR and AR directly stimulate cell 
growth, AR apparently indirectly exerts stimulation of 
EGFR synthesis by paracrine or autocrine mechanisms 
[46]. In addition to AR-EGFR crosstalk, Src kinase is 
implicated in EGFR phosphorylation [47]. Meanwhile, 
interaction between AR and the MAPK pathway has been 
demonstrated with HER2-AR-ERK feedback loops in 
breast cancer [48]. Naderi et al. has documented synergy 
between flutamide and the HER2 inhibitor AG825; 
and subsequently, synergy between flutamide and the 
MEK inhibitor CI-1040 [49, 50]. In a preclinical model, 
DHT enhanced IL-6 and IL-8 expression and flutamide 
abrogated IL-6 and IL-8 expression [51]. Darshan et al. 
suggested that taxanes, microtubule stabilization agents, 
are active in castrate-resistant prostate cancer and act by 
inhibiting AR trafficking and the downstream cascade of 
transcriptional events, including AR target genes such as 
prostate-specific antigen [52]. Testing this concept, Kuroda 
et al. [S8] treated a patient with metastatic AR-positive 
salivary duct carcinoma with combined anti-androgen 
treatment and paclitaxel, achieving a partial response. 
Other mechanisms promoting resistance may 
include genetic and epigenetic adaptation, clonal selection, 
and evolution of the tumor microenvironment in prostate 
cancer. The synthesis of constitutively active AR variants 
lacking the canonical ligand-binding domain may also 
promote resistance [53].
FUTURE DIRECTIONS
AR is ubiquitously expressed across malignancies. 
Drawing definitive conclusions about rates of expression 
is however challenging, mainly due to the lack of 
standardized AR measurement methods and the relatively 
small number of patients tested for AR expression. 
Importantly, there is a paucity of studies of androgen 
manipulation in AR+ tumors other than prostate cancer. 
Importantly, some tumors such as salivary gland ductal 
tumors have AR positivity rates approaching 100%. 
Anecdotal reports and small studies in a variety of 
malignancies suggest that AR-positive tumors may 
respond to hormonal manipulation. Of interest, breast 
and gynecologic tumors also have high rates of AR 
positivity (Table 1). The latter may have special clinical 
relevance [54], especially since aromatase inhibitors, used 
to suppress estrogen levels in patients with ER+ breast 
tumors, can raise testosterone levels. As an example, 
anastrozole increases testosterone levels by decreasing 
serum estradiol levels [55]. Finally, PIK3CA/AKT/mTOR 
signaling is ubiquitously deregulated in cancer, and it is 
apparent that there is significant crosstalk between this 
pathway and that related to androgens (Figure 3). Further 
exploration of androgen modulation in patients with 
diverse cancers merits investigation.
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